Your Directors have pleasure in presenting the 53rd Annual Report and Audited Senior Joint Commissioner,. Kolkata. Delhi Value Added Tax. Ranbaxy Laboratories Limited Annual Report CHAIRMAN’S MESSAGE Down Inc. Germany (upto 16 December ) 11 Ranbaxy Unichem Co. Get Ranbaxy Laboratories latest Balance Sheet, Financial Statements and Ranbaxy Laboratories detailed profit and loss accounts.

Author: Daizuru Dijas
Country: Reunion
Language: English (Spanish)
Genre: Education
Published (Last): 10 March 2015
Pages: 407
PDF File Size: 9.51 Mb
ePub File Size: 1.96 Mb
ISBN: 151-9-72136-722-8
Downloads: 44999
Price: Free* [*Free Regsitration Required]
Uploader: Visho

Your Account is not yet activated Click here to receive activation mail once again. We are attempting to resolve this funny technical issue! Further, the Company has deposited Rs. Related party disclosures A] Names of related parties Related parties where control exists with whom no transactions have taken place during the current period or previous year: Commitments i Estimated amount of contracts remaining to be executed on capital account and not This scheme limits the maximum grant of options to an employee or a director at 30, in any given year.

However, considering the above matters relating to the Toansa manufacturing facility, provisions primarily relating to inventories, trade commitments, sales return etc.

Ranbaxy Laboratories Limited (BSE Code: ) annual reports starting from year

Segment information In accordance with AS 17, Segment Reporting, segment information has been given in the consolidated fnancial statements of the Company, 20110-11 therefore, no separate disclosure on segment information is given in these fnancial statements. Nifty bounces over ; Bharti languishes 17 Feb 10 As per the Scheme, the share exchange ratio has been proposed as 0.

Ranbaxy UK Limited, U. ESOS I and II ranbacy that the grant price of options is to be determined at reporrt average of the daily closing price of the Company”s equity shares on the NSE during a period of 26 weeks preceding the date of the grant.


The Company expects to resume API bulk shipments to EU countries from Toansa manufacturing facility upon receipt of clearances from relevant regulatory authorities.

Options are granted at the discretion of the committee to selected employees depending upon certain criterion. Qnnual options vests evenly over a period of three years from the date of grant.

The Company has challenged the order before the Hon”ble Income Tax Appellate Tribunal ITAT and pending disposal of the matter, the management considers the amount of tax liability as unascertainable. You will be able to download it at any time during the subscription period.

The Company is fully cooperating with this information request and is in dialogue with the US DOJ for repory of the requisite information. The same is expected to be resumed shortly. Company overview Ranbaxy Laboratories Limited ”the Company” together with its subsidiaries and associates, operates as an integrated international pharmaceutical organisation with businesses encompassing the entire value chain in the marketing, production and distribution of pharmaceutical products.

Hedging and derivatives a The Company uses various forms of derivative instruments such as foreign exchange forward contracts including instruments which are in substance forward contractsoptions, currency annusl, currency cum interest rate swaps and interest rate swaps to hedge its exposure to movements in foreign exchange and interest rates.

The Company expects to resume the operations shortly. Daiichi Sankyo Propharma Co. It is the anhual exporter of bulk drugs and pharmaceutical dosag.

Ranbaxy Laboratories

Consequently, stock write off and other costs of Rs. It also includes a demand of Rs. The Company will issue shares annial the Trust which will allocate the shares to the respective employees upon exercise of stock options from time to time under ESOP – The Company received the fnal assessment order from the AO in November whereby demand of Rs The sales consideration of Rs.


Since the matter involves signifcant judgement and in view of the inherent uncertainty of the present situation, the actual amounts may differ eventually. Pursuant to the transaction, the Company has recorded a gain of Rs.

The ineffectiveness arising from cash fow hedges which was recognised in Statement of Proft and Loss was not material. In calculating these provisions, the management has used the best information and estimates, presently available.

Ranbaxy Laboratories Balance Sheet, Ranbaxy Laboratories Financial Statement & Accounts

The following are the outstanding derivative contracts entered into by the Company: Description cannot exceed characters. Ranbaxy Laboratories is not traded in the last 30 days.

Clicking on the download link will add the report to your downloaded reports. Nifty pares losses; Ranbaxy,Cipla lead 25 Sep 09 RANBAXY Business Profile Ranbaxy Laboratories manufactures and markets pharmaceutical dosage forms for human health careanimal health care products, bulk drugs and intermediates, diagnostics, laboratory chemicals and reagents. Free reports will not ranbxay deducted from your 20010-11.

Consequent to the fndings of the above exercise, the carrying amount of inventory has been written down by Rs.